Clinical Trial Update: MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction [Phase 2, Phase 3]

View source ↗

Summary

Ongoing Phase 2/3 clinical trial evaluating MitoQ for schizophrenia-spectrum disorders with mitochondrial dysfunction; recruitment is currently open.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Schizophrenia

Drugs mentioned

• MitoQ

Snippet

Sponsor: Mclean Hospital | Conditions: Schizophrenia and Related Disorders, Mitochondrial Alteration | Phase 2, Phase 3 | Status: RECRUITING